Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study Meeting Abstract
| Authors: | Kim, Y. H.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Wang, Y.; Palanca-Wessels, M.; Zagadailov, E.; Trepicchio, W. L.; Lin, H.; Little, M.; Prince, H. |
| Abstract Title: | Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study |
| Meeting Title: | 76th Annual Meeting of the Society for Investigative Dermatology (SID) |
| Journal Title: | Journal of Investigative Dermatology |
| Volume: | 137 |
| Issue: | 5 Suppl. 1 |
| Meeting Dates: | 2017 Apr 26-29 |
| Meeting Location: | Portland, OR |
| ISSN: | 0022-202X |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2017-05-01 |
| Start Page: | S45 |
| Language: | English |
| ACCESSION: | WOS:000406862400261 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jid.2017.02.278 |
| Notes: | Meeting Abstract: 262 -- Source: Wos |
